Compare Stocks: DMRA, CGON, ORKA, and SRRK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$74.62 -1.3%	$74.06	$35.64 ▼ $80.97	$6.61B	0.24	665,333 shs	1.78 million shs
DMRA Damora Therapeutics, Inc. Common Stock	$22.59 -0.8%	$29.33	$2.77 ▼ $38.33	$1.39B	1.46	469,673 shs	3.32 million shs
ORKA Oruka Therapeutics	$94.96 -2.8%	$96.40	$14.89 ▼ $115.51	$6.29B	-0.34	746,357 shs	1.94 million shs
SRRK Scholar Rock	$46.65 -4.8%	$52.84	$27.07 ▼ $61.76	$5.68B	0.67	1.68 million shs	3.25 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	+3.14%	-3.85%	+22.17%	+97.83%
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	-19.61%	-25.47%	+6.41%	+692.63%
ORKA Oruka Therapeutics	0.00%	+2.79%	-9.44%	+31.27%	+485.81%
SRRK Scholar Rock	0.00%	-15.81%	-15.57%	-1.44%	+46.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$74.62 -1.3%	$74.06	$35.64 ▼ $80.97	$6.61B	0.24	665,333 shs	1.78 million shs
DMRA Damora Therapeutics, Inc. Common Stock	$22.59 -0.8%	$29.33	$2.77 ▼ $38.33	$1.39B	1.46	469,673 shs	3.32 million shs
ORKA Oruka Therapeutics	$94.96 -2.8%	$96.40	$14.89 ▼ $115.51	$6.29B	-0.34	746,357 shs	1.94 million shs
SRRK Scholar Rock	$46.65 -4.8%	$52.84	$27.07 ▼ $61.76	$5.68B	0.67	1.68 million shs	3.25 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	+3.14%	-3.85%	+22.17%	+97.83%
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	-19.61%	-25.47%	+6.41%	+692.63%
ORKA Oruka Therapeutics	0.00%	+2.79%	-9.44%	+31.27%	+485.81%
SRRK Scholar Rock	0.00%	-15.81%	-15.57%	-1.44%	+46.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.73	Moderate Buy	$87.78	17.63% Upside
DMRA Damora Therapeutics, Inc. Common Stock	3.00	Buy	$44.00	94.78% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$133.00	40.06% Upside
SRRK Scholar Rock	3.00	Buy	$66.00	41.48% Upside

Current Analyst Ratings Breakdown

Latest DMRA, CGON, ORKA, and SRRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2026	SRRK Scholar Rock	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/15/2026	SRRK Scholar Rock	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$72.00
9/15/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$64.00
9/15/2026	SRRK Scholar Rock	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$60.00 ➝ $75.00
9/15/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$65.00 ➝ $70.00
9/15/2026	SRRK Scholar Rock	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
9/14/2026	SRRK Scholar Rock	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$55.00 ➝ $58.00
9/14/2026	SRRK Scholar Rock	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$57.00 ➝ $65.00
9/14/2026	DMRA Damora Therapeutics, Inc. Common Stock	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	SRRK Scholar Rock	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/14/2026	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$76.00 ➝ $84.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,637.21	N/A	N/A	$9.33 per share	8.00
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$3.37	N/A	N/A	N/A	N/A	-176.39%	-77.86%	N/A
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	11/13/2026 (Estimated)

Latest DMRA, CGON, ORKA, and SRRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
DMRA Damora Therapeutics, Inc. Common Stock	N/A	19.73	19.73
ORKA Oruka Therapeutics	N/A	38.51	38.51
SRRK Scholar Rock	0.77	7.02	7.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
ORKA Oruka Therapeutics	56.44%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
ORKA Oruka Therapeutics	23.49%
SRRK Scholar Rock	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.74 million	61.49 million	No Data
ORKA Oruka Therapeutics	68	66.21 million	50.66 million	N/A
SRRK Scholar Rock	289	121.79 million	109.24 million	Optionable

DMRA, CGON, ORKA, and SRRK Headlines

Recent News About These Companies

Analysts Offer Predictions for Scholar Rock FY2026 Earnings

September 19 at 1:13 AM | americanbankingnews.com

Scholar Rock Holding (SRRK) Receives a Buy from Piper Sandler

September 17 at 7:35 PM | theglobeandmail.com

Scholar Rock (NASDAQ:SRRK) Raised to Strong-Buy at Jefferies Financial Group

September 17 at 7:29 AM | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Scholar Rock

September 17 at 7:11 AM | marketbeat.com

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

September 16, 2026 | insidermonkey.com

Wedbush Reaffirms "Outperform" Rating for Scholar Rock (NASDAQ:SRRK)

September 16, 2026 | americanbankingnews.com

Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions

September 15, 2026 | finance.yahoo.com

Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says

September 15, 2026 | finance.yahoo.com

Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

September 15, 2026 | seekingalpha.com

Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy

September 15, 2026 | msn.com

Scholar Rock (NASDAQ:SRRK) Shares Down 7.1% - Here's What Happened

September 15, 2026 | marketbeat.com

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

September 15, 2026 | benzinga.com

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets

September 14, 2026 | finance.yahoo.com

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

September 14, 2026 | seekingalpha.com

Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says

September 14, 2026 | finance.yahoo.com

Scholar Rock says its first muscle-targeted SMA therapy will cost about $310,000 annually

September 14, 2026 | msn.com

Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell

September 14, 2026 | finance.yahoo.com

Scholar Rock wins FDA approval for Isembyld

September 14, 2026 | thepharmaletter.comT

Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy

September 14, 2026 | finance.yahoo.com

Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

September 14, 2026 | benzinga.com

Scholar Rock's (SRRK) Outperform Rating Reaffirmed at Wedbush

September 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, CGON, ORKA, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

$74.62 -1.00 (-1.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$72.49 -2.13 (-2.85%)

As of 09/18/2026 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$22.59 -0.19 (-0.83%)

As of 09/18/2026 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Oruka Therapeutics NASDAQ:ORKA

$94.96 -2.77 (-2.83%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$95.00 +0.04 (+0.04%)

As of 09/18/2026 07:30 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Scholar Rock NASDAQ:SRRK

$46.65 -2.37 (-4.83%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$46.72 +0.07 (+0.15%)

As of 09/18/2026 07:49 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMRA, CGON, ORKA, and SRRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMRA, CGON, ORKA, and SRRK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMRA, CGON, ORKA, and SRRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, CGON, ORKA, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Oruka Therapeutics NASDAQ:ORKA

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMRA, CGON, ORKA, and SRRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMRA, CGON, ORKA, and SRRK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMRA, CGON, ORKA, and SRRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, CGON, ORKA, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Oruka Therapeutics NASDAQ:ORKA

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools